Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewML 311
Description: Inhibits Mcl-1-BIM interaction
Chemical Name: 7-[(4-Ethyl-1-piperazinyl)[4-(trifluoromethyl)phenyl]methyl]-8-quinolinol
Purity: ≥99% (HPLC)
Biological Activity for ML 311
ML 311 is an inhibits Mcl1-BIM interaction. Inhibits viability of Mcl1-dependent tumor cell lines. Induces cell death and decreased spheroid formation in Her2 positive breast cancer cells.
Technical Data for ML 311
| M. Wt | 415.45 |
| Formula | C23H24F3N3O |
| Storage | Store at -20°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 315698-17-0 |
| PubChem ID | 3384730 |
| InChI Key | NGAPBLRRJSKIRT-UHFFFAOYSA-N |
| Smiles | CCN(CC1)CCN1C(C2=CC=C(C(F)(F)F)C=C2)C3=C(O)C4=NC=CC=C4C=C3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for ML 311
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 20.77 | 50 | |
| ethanol | 20.77 | 50 |
Preparing Stock Solutions for ML 311
The following data is based on the product molecular weight 415.45. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 4.81 mL | 24.07 mL | 48.14 mL |
| 2.5 mM | 0.96 mL | 4.81 mL | 9.63 mL |
| 5 mM | 0.48 mL | 2.41 mL | 4.81 mL |
| 25 mM | 0.1 mL | 0.48 mL | 0.96 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for ML 311
References for ML 311
References are publications that support the biological activity of the product.
Bashari et al (2016) Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Res. 18 26 PMID: 26921175
Bannister et al (2012) ML311: A small molecule that potently and selectively disrupts the protein-protein interaction of Mcl-1 and Bim: a probe for studying lymphoid tumorigenesis. Probe Reports from the NIH Molecular Libraries Program PMID: 23762927
If you know of a relevant reference for ML 311, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: ML 311, ML 311 supplier, ML311, myeloid, cell, leukemia, 1, mcl1, BIM, inhibitors, inhibits, interaction, Bcl-2, Family, 5733, Tocris Bioscience
Citations for ML 311
Citations are publications that use Tocris products.
Currently there are no citations for ML 311. Do you know of a great paper that uses ML 311 from Tocris? Please let us know.
Reviews for ML 311
There are currently no reviews for this product. Be the first to review ML 311 and earn rewards!
Have you used ML 311?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.
Pathways for ML 311
